The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Our mission is to support the development of Clinical Psychology, both as a profession and as a body of knowledge and skills. By working collaboratively with a number of organisations including the ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

A temporary freeze on meetings on the National Institutes of Health could lead to delays in disbursing research grants and in ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...